Bulkamid™ Urethral Bulking System

Name: Bulkamid™ Urethral Bulking System
Brand: Boston Scientific

Bulkamid is a minimally invasive, long-lasting treatment option to treat bladder leaks caused by stress urinary incontinence (SUI). Bulkamid is a non-particulate homogeneous hydrogel consisting of 97.5% water and 2.5% cross-linked polyacrylamide.

Explore product details

Reimbursement

Bulkamid reimbursement guide

Configure or select a product to continue to order

Instructions for use are found inside the product packaging.

Go to customer support

Overview
Clinical data
Technical specifications
Resources
Ordering information

Why choose Bulkamid?

Bulkamid is a unique bulking agent.

Unique composition

Bulkamid is a non-particulate homogeneous hydrogel consisting of 97.5% water and 2.5% cross-linked polyacrylamide.

Precision delivery system

The Bulkamid delivery system was designed to provide a reproducible, efficient, predictable injection procedure.

Long lasting

Designed to effectively treat SUI, with clinical support up to 7 years.¹

Bulkamid™ Urethral Bulking | Step‑by‑Step Procedure

This animation demonstrates the Bulkamid procedure.

In one study, 64% of women chose Bulkamid to treat their SUI over other options.²

Pie chart showing 64% of women chose Bulkamid and 36% chose alternative surgical interventions.

What’s included

Advantage™ Fit Transvaginal Mid-Urethral Sling System product shot.

The kit includes:

2x 1 mL Bulkamid syringes
2x 23G, 12 cm needles
1x Bulkamid rotatable sheath

Additional components include:

Bulkamid Cystoscope sterilization container
Zero-degree Bulkamid cystoscope with universal connections
Universal adapters to fit all light cables
Protection sheath for transportation

Studies and data

Lose G, Sørensen HC, Axelsen SM, Falconer C, Lobodasch K, Safwat T. An open multicenter study of polyacrylamide hydrogel (Bulkamid®) for female stress and mixed urinary incontinence.
Int Urogynecol J. 2010;21(12):1471–1477.
https://pubmed.ncbi.nlm.nih.gov/20645077/

Toozs-Hobson P, Al‑Singary W, Fynes M, Tegerstedt G, Lose G. Two-year follow-up of an open-label multicenter study of polyacrylamide hydrogel (Bulkamid®) for female stress and stress‑predominant mixed incontinence. Int Urogynecol J. 2012;23(10):1373–1378.
https://pubmed.ncbi.nlm.nih.gov/22531952/

Leone Roberti Maggiore U, Alessandri F, Medica M, Gabelli M, Venturini PL, Ferrero S. Periurethral injection of polyacrylamide hydrogel for the treatment of stress urinary incontinence: impact on female sexual function. J Sex Med. 2012;9(12):3255–3263.
https://www.sciencedirect.com/science/article/abs/pii/S1743609515338418

Leone Roberti Maggiore U, Alessandri F, Medica M, Gabelli M, Venturini PL, Ferrero S. Outpatient periurethral injections of polyacrylamide hydrogel for female stress urinary incontinence: effectiveness and safety. Arch Gynecol Obstet. 2013;288(1):131–137.
https://pubmed.ncbi.nlm.nih.gov/23371485/

Sokol ER, Karram MM, Dmochowski R. Efficacy and safety of polyacrylamide hydrogel for the treatment of female stress incontinence: randomized, prospective, multicenter North American study. J Urol. 2014;192(3):843–849.
https://pubmed.ncbi.nlm.nih.gov/24704117/

Pai A, Al‑Singary W. Durability, safety and efficacy of polyacrylamide hydrogel (Bulkamid®) in stress and mixed urinary incontinence: 3‑year follow‑up. Cent European J Urol. 2015;68(4):428–433.
https://pubmed.ncbi.nlm.nih.gov/26855795/

Itkonen Freitas AM, Mentula M, Rahkola‑Soisalo P, Tulokas S, Mikkola TS. TVT vs PAHG for primary SUI: randomized clinical trial. J Urol. Epub 2019 (print 2020).
https://pubmed.ncbi.nlm.nih.gov/31479396/

Dwyer et al. “Voice your choice”: Women’s choice of surgery for primary SUI. Int Urogynecol J. 2020;31:769–777.
https://pubmed.ncbi.nlm.nih.gov/31853598/

Itkonen Freitas AM et al. TVT vs PAHG for primary SUI — RCT. J Urol. 2020;203(2):372–378.
https://pubmed.ncbi.nlm.nih.gov/31479396/

Brosche T, Kuhn A, Lobodasch K, Sokol ER. Seven‑year efficacy and safety outcomes of Bulkamid for SUI. Neurourol Urodyn. 2021;40(1):502–508.
https://pubmed.ncbi.nlm.nih.gov/33410544/

Hoe V, Yao HH, Gough K, O’Connell HE. Long‑term outcomes of polyacrylamide hydrogel treatment in women with SUI. BJU Int. 2022;130(Suppl 1):22–24.
https://pubmed.ncbi.nlm.nih.gov/35199441/

Itkonen Freitas AM et al. TVT vs PAHG — 3‑year follow‑up from RCT. J Urol. 2022;208:658–667.
https://pubmed.ncbi.nlm.nih.gov/35942796/

Köseoğlu E, Kılıç M, Acar Ö, Tarcan T. Minimally invasive treatment of female SUI with PAHG: Turkish cohort including mixed UI and prior failed surgery. J Urol Surg. 2023;10(4):334–340.
https://jurolsurgery.org/pdf/a426c3a3-a110-40af-a6dd-1b2b563ce9ac/articles/jus.galenos.2023.2023-5-3/JUS-10-334-En.pdf

Uleri A, Marchand F, Cherasse A, et al. One‑year outcomes of PAHG injection in women with stress and mixed UI. World J Urol. 2024;42:518.
https://link.springer.com/article/10.1007/s00345-024-05221-9

Itkonen Freitas A‑M, Isaksson C, Rahkola‑Soisalo P, Mentula M, Mikkola TS. TVT vs PAHG — 5‑year follow‑up. NEJM Evidence. 2025;4(5).
https://researchportal.helsinki.fi/en/publications/tension-free-vaginal-tape-versus-polyacrylamide-hydrogel-injectio/

Lamblin G, Boix S, Moret S, Nohuz E, Chene G, Hamid D. Effectiveness and safety of urethral bulking with Bulkamid®: French multicenter cohort. Int Urogynecol J. 2025;36:205–211.
https://pubmed.ncbi.nlm.nih.gov/39656238/

Faurie B, Hascoet J, Richard C, et al. Outpatient PAHG injections under local anesthesia: prospective single‑center series. Urology. 2025;198:8–13.
https://pubmed.ncbi.nlm.nih.gov/39580117/

Technical specifications